Literature DB >> 24761074

Utility of single photon emission tomography/computed tomography in characterizing an additional focus of iodine uptake in post-treatment whole body iodine scan.

Vinod Kumar Mozhikunnam Chandran1, Thomas Soujya1, Chidambaram Natrajan Balasubramanian Harisankar1.   

Abstract

Entities:  

Year:  2014        PMID: 24761074      PMCID: PMC3996772          DOI: 10.4103/0972-3919.130325

Source DB:  PubMed          Journal:  Indian J Nucl Med        ISSN: 0974-0244


× No keyword cloud information.
Sir, A 27-year-old female, a known case of follicular variant of papillary thyroid cancer (pT2, Nx, M0) was referred to nuclear medicine department after thyroidectomy. She underwent whole body iodine scanning 48 h after oral administration of 74 MBq of 131-Iodine. There was iodine avid residual thyroid tissue and cervical lymph nodal metastases in the neck. No other site of abnormal iodine avidity was noted. Patient was treated with high dose radioiodine (100 mCi) in another center. Post-therapy scans acquired after 7 days at our center showed a focus of tracer uptake in the left side of face [Figure 1]. Hybrid single photon emission tomography/computed tomography (SPECT/CT) imaging localized the uptake to a mucosal thickening in the left maxillary sinus [Figure 1 arrow]. A detailed history from the patient revealed that the patient developed upper respiratory infection and features of left maxillary sinusitis after the high dose therapy. The accumulation in the left maxillary sinus was attributed to the sinusitis, which was also evident on SPECT/CT images.
Figure 1

Whole body images (anterior view) of pre-radioiodine therapy scan (a) Post-treatment scan (b) Along with computed tomography (CT) images of the head in coronal (c) Sagittal (d) and axial (e) Views and fused single photon emission tomography/CT images of the head in coronal (f) Sagittal (g) and axial (h) Views showing tracer accumulation in the left maxillary sinus. Also note is minimal mucosal thickening in the left maxillary sinus (arrow)

Whole body images (anterior view) of pre-radioiodine therapy scan (a) Post-treatment scan (b) Along with computed tomography (CT) images of the head in coronal (c) Sagittal (d) and axial (e) Views and fused single photon emission tomography/CT images of the head in coronal (f) Sagittal (g) and axial (h) Views showing tracer accumulation in the left maxillary sinus. Also note is minimal mucosal thickening in the left maxillary sinus (arrow) Iodine is actively taken up into the thyroid follicles by sodium iodine symporter (NIS).[1] NIS is expressed at the highest level in the thyroid and lactating breast.[2] NIS is also expressed in the salivary glands, nasal mucosa, lacrimal sac and nasolacrimal ducts.[3] The expression of NIS and the ability to trap iodine explains the retention of radioiodine in maxillary sinus in this patient with maxillary sinusitis. SPECT/CT is of benefit in variety of thyroid diseases.[4567] Although post-therapy scanning can identify new sites of metastases that were missed in pre-therapy scanning in 10-26% of the patients,[8] it must be remembered that not all new sites noted are due to metastatic disease.
  8 in total

1.  Hybrid SPECT/CT evaluation of Marine-Lenhart syndrome.

Authors:  Chidambaram Natrajan Balasubramanian Harisankar; Govindababu Rajalakshmi Preethi; Biju Baby Chungath
Journal:  Clin Nucl Med       Date:  2013-02       Impact factor: 7.794

2.  Hybrid SPECT/CT evaluation of dual ectopia of thyroid in the absence of orthotopic thyroid gland.

Authors:  Chidambaram Natrajan Balasubramanian Harisankar; Govindababu Rajalakshmi Preethi; Mv George
Journal:  Clin Nucl Med       Date:  2012-06       Impact factor: 7.794

3.  Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer?

Authors:  V Fatourechi; I D Hay; B P Mullan; G A Wiseman; G Z Eghbali-Fatourechi; L M Thorson; C A Gorman
Journal:  Thyroid       Date:  2000-07       Impact factor: 6.568

Review 4.  Enhancement of sodium/iodide symporter expression in thyroid and breast cancer.

Authors:  T Kogai; K Taki; G A Brent
Journal:  Endocr Relat Cancer       Date:  2006-09       Impact factor: 5.678

Review 5.  The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics.

Authors:  Takahiko Kogai; Gregory A Brent
Journal:  Pharmacol Ther       Date:  2012-06-29       Impact factor: 12.310

6.  Expression of sodium iodide symporter in the lacrimal drainage system: implication for the mechanism underlying nasolacrimal duct obstruction in I(131)-treated patients.

Authors:  Kenneth E Morgenstern; Douangsone D Vadysirisack; Zhaoxia Zhang; Kenneth V Cahill; Jill A Foster; John A Burns; Richard T Kloos; Sissy M Jhiang
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2005-09       Impact factor: 1.746

7.  Utility of Iodine-131 hybrid SPECT-CT fusion imaging before high-dose radioiodine therapy in papillary thyroid carcinoma.

Authors:  Anish Bhattacharya; Sunil Hejjaji Venkataramarao; Chandra Sekhar Bal; Bhagwant Rai Mittal
Journal:  Indian J Nucl Med       Date:  2010-01

8.  Dual ectopic thyroid in the presence of atrophic orthotopic thyroid gland in a patient with acquired hypothyroidism: Evaluation with hybrid Single-Photon Emission Computed Tomography/Computed Tomography.

Authors:  Chidambaram Natrajan Balasubramanian Harisankar
Journal:  Indian J Nucl Med       Date:  2013-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.